Intercept launches with $500M to attack colds, flu and indoor-air transmission
Nan Ransohoff, Charlie Petty and Devin Sok are using grants, investments and buyer demand to pull respiratory prevention out of a funding gap.
By Ryan Merket · Published
Primary source: Intercept
Why it matters
Intercept is a test of whether the Frontier-style market-making model can work in health: fund the science, organize buyers early and make broad prevention investable before pharma would normally step in.
Nan Ransohoff (@nanransohoff), Charlie Petty and Devin Sok launched Intercept on June 24th as a $500 million philanthropic initiative aimed at reducing respiratory infections through broad-spectrum preventatives and cleaner indoor air.…
When you purchase through links in our articles, we may earn a small commission. This doesn’t affect our editorial independence.